Clinical Trial Update: Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs' Dystrophy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating ripasudil to enhance corneal clearing after Descemet Membrane Endothelial Keratoplasty in Fuchs' endothelial dystrophy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fuchs Endothelial Dystrophy

Drugs mentioned

• Ripasudil (Ripasudil)

Snippet

Sponsor: Michael D. Straiko, MD | Conditions: Fuchs Endothelial Dystrophy | Phase 2 | Status: UNKNOWN